儿童肺炎支原体混合感染特征及其短期预后风险分析

doi:10.12183/j.scjpm.2025.1025

摘要/Abstract

摘要： 目的调查儿童肺炎支原体（MP）混合感染及预后情况,并分析MP混合感染对短期预后的影响。方法 2023年5月至2024年11月,选择首都医科大学附属北京友谊医院收治的305例MP感染患儿为研究对象,调查儿童MP混合感染情况,跟踪随访患儿确诊并开始治疗后30d内预后情况。使用统一调查表收集所有MP患儿一般资料、实验室指标及影像学资料,通过多因素logistic回归模型分析儿童MP混合感染对预后的影响。结果 305例MP感染患儿中,仅MP感染198例（64.92%）,混合感染107例（35.08%）,其中MP+病毒感染74例（24.26%）,MP+细菌感染33例（10.82%）。305例MP感染患儿中,预后不良86例（28.20%）,预后良好219例（71.80%）。多因素logistic回归分析结果显示,在调整协变量后,与无混合感染比较,MP+病毒感染、MP+细菌感染会增加儿童MP预后不良风险（P<0.05）,其OR及95%CI分别为4.610（2.339~9.086）、4.432（2.381~8.692）。结论儿童MP感染后有部分为混合感染,相较于单纯MP感染,混合感染会对患儿预后产生不良影响。

关键词: 儿童, 肺炎支原体, 混合感染, 预后

中图分类号:

R181.3

王莹, 田雨飞, 赵亚坤. 儿童肺炎支原体混合感染特征及其短期预后风险分析[J]. 华南预防医学, 2025, 51(9): 1025-1029.

参考文献

[1] Liu X, Xu W, Meng L, et al.Development and validation of a machine learning model for predicting co-infection of Mycoplasma pneumoniae in pediatric patients[J]. Transl Pediatr, 2025, 14(6): 1201-1212.
[2] Ding G, Zhang X, Vinturache A, et al.Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia[J]. Eur J Pediatr, 2024, 183(7): 3001-3011.
[3] Wang Y, Yu X, Liu F, et al.Respiratory microbiota imbalance in children with Mycoplasma pneumoniae pneumonia[J]. Emerg Microbes Infect, 2023, 12(1): 2202272.
[4] Lv G, Shi L, Liu Y, et al.Epidemiological characteristics of common respiratory pathogens in children[J]. Sci Rep, 2024, 14(1): 16299.
[5] Lv W, Guo C, Lv G, et al.Epidemiological characteristics and related risk factors of mixed infection in children with Mycoplasma pneumoniae pneumonia[J]. New Microbiol, 2024, 47(3): 251-257.
[6] 中华人民共和国国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 国际流行病学传染病学杂志,2023,50(2):79-85.
[7] 中华医学会儿科学分会呼吸学组,中华儿科杂志编辑委员会,中国医药教育协会儿科专业委员会. 儿童社区获得性肺炎管理指南(2024修订)[J]. 中华儿科杂志,2024,62(10):920-930.
[8] Fan F, Lv J, Yang Q, et al.Clinical characteristics and serum inflammatory markers of community-acquired Mycoplasma pneumoniaee pneumonia in children[J]. Clin Respir J, 2023, 17(7): 607-617.
[9] 曾希,蒋婷婷,汤鹤,等. 社区获得性肺炎儿童的肺炎支原体合并其他病原感染临床特征分析[J]. 标记免疫分析与临床,2025,32(1):12-18.
[10] 毛璐易,王宇清. 肺炎支原体肺炎住院患儿混合感染的临床研究及危险因素分析[J]. 中国儿童保健杂志,2019,27(8):917-919,926.
[11] Yuan L, Mingyue D, Zhou L.Analysis of the characteristics of mixed infections with Mycoplasma pneumoniae in children[J]. Sci Rep, 2025, 15(1): 9414.
[12] Yan C, Xue GH, Zhao HQ, et al.Current status of Mycoplasma pneumoniae infection in China[J]. World J Pediatr, 2024, 20(1): 1-4.
[13] Shin S, Koo S, Yang YJ, et al.Characteristics of the Mycoplasma pneumoniae epidemic from 2019 to 2020 in Korea: Macrolide resistance and co-infection trends[J]. Antibiotics (Basel), 2023, 12(11): 1623.
[14] Yildirim Arslan S, Yildiz G.Rhinovirus and Mycoplasma pneumoniae co-infection in pediatric patients: Atypical presentations with renal complications[J]. Pediatr Infect Dis J, 2025, 44(4): e145.
[15] Tran Quang K, Tran Do H, Pham Hung V, et al.Study on the co-infection of children with severe community-acquired pneumonia[J]. Pediatr Int, 2022, 64(1): e14853.
[16] Li F, Kong S, Xie K, et al.High ratio of C-reactive protein/procalcitonin predicts Mycoplasma pneumoniae infection among adults hospitalized with community-acquired pneumonia[J]. Scand J Clin Lab Invest, 2021, 81(1): 65-71.
[17] Yi X, Jia W, Li W, et al.Diagnostic value of cytokines in severe childhood Mycoplasma pneumoniae pneumonia combined with adenovirus infection[J]. Ital J Pediatr, 2024, 50(1): 92.
[18] Korneenko E, Rog I, Chudinov I, et al.Antibiotic resistance and viral co-infection in children diagnosed with pneumonia caused by Mycoplasma pneumoniae admitted to Russian hospitals during October 2023-February 2024[J]. BMC Infect Dis, 2025, 25(1): 363.
[19] Wang YS, Zhou YL, Bai GN, et al.Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children[J]. World J Pediatr, 2024, 20(9): 901-914.
[20] Chen Y, Zhang Y, Tang QN, et al.Efficacy of doxycycline therapy for macrolide-resistant Mycoplasma pneumoniae pneumonia in children at different periods[J]. Ital J Pediatr, 2024, 50(1): 38.